Eğitim Bilgileri
1998 - 2001
1998 - 2001Tıpta Yandal Uzmanlık
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
1992 - 1998
1992 - 1998Tıpta Uzmanlık
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
Akademik Unvanlar / Görevler
2004 - 2009
2004 - 2009Doç. Dr.
İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı
2001 - 2005
2001 - 2005Uzman
İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı
1992 - 1997
1992 - 1997Uzman
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
1985 - 1991
1985 - 1991Öğretim Görevlisi Dr.
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Yönetimsel Görevler
2006 - 2010
2006 - 2010Enstitü Müdür Yardımcısı
İstanbul Üniversitesi
Verdiği Dersler
SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler
2024
2024Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women with Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Mahidin E. I. B. M., Im S., Rihani J., Chung W., Babu K. G., Bowles J., et al.
Journal of Clinical Oncology
, cilt.42, sa.23, ss.2812-2821, 2024 (SCI-Expanded)
2024
2024A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Cicin I., et al.
MEDICINE
, cilt.103, sa.21, 2024 (SCI-Expanded)
2023
2023Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
Guner G., Aktas B. Y., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded)
2023
2023Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review
ERALP Y., Ates U.
Vaccines
, cilt.11, sa.10, 2023 (SCI-Expanded)
2023
2023Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
DOĞAN İ., AKSOY S., ÇAKAR B., BAŞARAN G., Ercelep O., Mandel N. M., et al.
CANCERS
, sa.6, 2023 (SCI-Expanded)
2022
2022Lung Cancer in Turkey
KAYI CANGIR A., Yumuk P. F., SAK S., AKYÜREK S., ERALP Y., Yilmaz U., et al.
JOURNAL OF THORACIC ONCOLOGY
, cilt.17, sa.10, ss.1158-1170, 2022 (SCI-Expanded)
2022
2022Application of mRNA Technology in Cancer Therapeutics
ERALP Y.
VACCINES
, cilt.10, sa.8, 2022 (SCI-Expanded)
2022
2022Laterality and survival in mesothelioma: A SEER database analysis.
Parekh J., Yerlikaya A., Xie Y., Eralp Y., Adjepong Y.
JOURNAL OF CLINICAL ONCOLOGY
, sa.16, 2022 (SCI-Expanded)
2022
2022International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials
Smeltzer M. P., Scagliotti G., Wakelee H. A., Mitsudomi T., Roy U. B., Clark R. C., et al.
JOURNAL OF THORACIC ONCOLOGY
, cilt.17, sa.5, ss.651-660, 2022 (SCI-Expanded)
2022
2022Factors predicting a lower likelihood of residual nodal disease in clinically-node positive patients undergoing sentinel node surgery after neoadjuvant chemotherapy for breast cancer
Cabioglu N., KARANLIK H., Igci A., Muslumanoglu M., TÜKENMEZ M., EMİROĞLU S., et al.
CANCER RESEARCH
, sa.4, 2022 (SCI-Expanded)
2021
2021Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center
AK N., Toker A., KARA M., ÖZKAN B., Ulker M., Kaba E., et al.
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
, cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded)
2021
2021The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.
Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded)
2021
2021TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.
BMC CANCER
, cilt.21, sa.1, 2021 (SCI-Expanded)
2021
2021GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients
Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.
JOURNAL OF THORACIC ONCOLOGY
, cilt.16, sa.3, 2021 (SCI-Expanded)
2021
2021Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvan chemotherapy in patients with locally advanced triple negative breast cancer
CABIOĞLU N., ÖNDER S., Oner G., Karatay H., TÜKENMEZ M., Muslumanoglu M., et al.
CANCER RESEARCH
, sa.4, 2021 (SCI-Expanded)
2020
2020GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.
LUNG CANCER
, cilt.148, ss.48-54, 2020 (SCI-Expanded)
2020
2020Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., et al.
Balkan medical journal
, cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded)
2019
2019Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
Papadopoulou E., Tsoulos N., Tsantikidi K., Metaxa-Mariatou V., Stamou P. E., Kladi-Skandali A., et al.
PLOS ONE
, cilt.14, sa.12, 2019 (SCI-Expanded)
2019
2019Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., et al.
JOURNAL OF THORACIC ONCOLOGY
, sa.10, 2019 (SCI-Expanded)
2019
2019The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study
Eralp Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., DEMİRKAZIK A., et al.
JOURNAL OF THORACIC ONCOLOGY
, sa.10, 2019 (SCI-Expanded)
2019
2019Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center
AK N., Toker A., Bayraktar S., ÖZKAN B., ÜLKER M. G., Dagoglu N., et al.
JOURNAL OF THORACIC ONCOLOGY
, sa.10, 2019 (SCI-Expanded)
2018
2018Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P., ÇİÇİN İ., et al.
JOURNAL OF THORACIC ONCOLOGY
, sa.10, 2018 (SCI-Expanded)
2018
2018Possible role of stress, coping strategies, and life style in the development of breast cancer
YILDIRIM N., ÖZKAN M., Ilgun A. S., Sarsenov D., Alco G., Aktepe F., et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
, cilt.53, sa.3, ss.207-220, 2018 (SCI-Expanded)
2018
2018Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer
Iyigun Z. E., Duymaz T., Ilgun A. S., Alco G., Ordu C., Sarsenov D., et al.
LYMPHATIC RESEARCH AND BIOLOGY
, cilt.16, sa.1, ss.28-35, 2018 (SCI-Expanded)
2016
2016Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients
Ilgun S., Sarsenov D., Erdogan Z., Ordu C., Celebi F., Pilanci K. N., et al.
JOURNAL OF BUON
, cilt.21, sa.6, ss.1425-1432, 2016 (SCI-Expanded)
2016
2016Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., et al.
MEDICINE
, cilt.95, sa.30, 2016 (SCI-Expanded)
2015
2015Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment
AYDINER A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., et al.
MEDICINE
, cilt.94, sa.52, 2015 (SCI-Expanded)
2015
2015The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer
ÖZMEN V., ÖZÇINAR B., Bozdogan A., Eralp Y., YAVUZ E., DİNÇER M. Z.
EJSO
, cilt.41, sa.10, ss.1368-1372, 2015 (SCI-Expanded)
2015
2015Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)
Icli F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., SAİP P. M., et al.
BREAST CANCER
, cilt.22, sa.5, ss.480-485, 2015 (SCI-Expanded)
2015
2015Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?
Pilanci K. N., Alco G., Ordu C., Sarsenov D., Celebi F., Erdogan Z., et al.
MEDICINE
, cilt.94, sa.18, 2015 (SCI-Expanded)
2014
2014Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy
GEZER U., Keskin S., Igci A., TÜKENMEZ M., Tiryakioglu D., Cetinkaya M., et al.
ONCOLOGY LETTERS
, cilt.8, sa.2, ss.845-848, 2014 (SCI-Expanded)
2014
2014Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?
Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., et al.
TUMOR BIOLOGY
, cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded)
2013
2013Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: A multicentric Turkish Oncology Group (TOG) trial
SAİP P. M., Eralp Y., AYDOĞMUŞ ŞEN F., Karaca H., ÖZKAN M., ÇETİN B. E., et al.
BREAST
, cilt.22, sa.5, ss.628-633, 2013 (SCI-Expanded)
2013
2013A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded)
2013
2013Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer
Eralp Y., Keskin S., YÖRÜKER E. E., Akisik E., Igci A., Muslumanoglu M., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded)
2012
2012Association of clinical and pathological variables with survival in thymoma
AYDINER A., Toker A., Sen F., Bicakci E., KAYTAN SAĞLAM E., Erus S., et al.
MEDICAL ONCOLOGY
, cilt.29, sa.3, ss.2221-2228, 2012 (SCI-Expanded)
2012
2012Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain
Altundag K., DİZDAR Ö., Ozsaran Z., Ozkok S., Saip P., Eralp Y., et al.
Onkologie
, cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded)
2011
2011Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study
Aydiner A., Sen F., KAYTAN SAĞLAM E., Oral E. N., Eralp Y., TAŞ F., et al.
CLINICAL LUNG CANCER
, cilt.12, sa.5, ss.286-292, 2011 (SCI-Expanded)
2011
2011Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients
Saip P., Sen F., Vural B., Ugurel E., Demirkan A., Derin D., et al.
JOURNAL OF BUON
, cilt.16, sa.2, ss.241-246, 2011 (SCI-Expanded)
2011
2011Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy
Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., et al.
ONCOLOGY
, cilt.81, sa.1, ss.30-38, 2011 (SCI-Expanded)
2009
2009Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors
Cicin I., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
, cilt.146, sa.2, ss.210-214, 2009 (SCI-Expanded)
2009
2009Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis
Saip P., Cicin I., Eralp Y., Karagol H., Kucucuk S., Alas R. C., et al.
JOURNAL OF NEURO-ONCOLOGY
, cilt.93, sa.2, ss.243-251, 2009 (SCI-Expanded)
2009
2009Malignant Ovarian Germ Cell Tumors A Single-Institution Experience
Cicin I., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.32, sa.2, ss.191-196, 2009 (SCI-Expanded)
2009
2009Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer.
Karagol H., Saip P., Eralp Y., Topuz S., Berkman S., Ilhan R., et al.
Tumori
, cilt.95, ss.207-11, 2009 (SCI-Expanded)
2009
2009Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger
Eralp Y., Smith T. L., Altundag K., Kau S., Litton J., Valero V., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.135, sa.1, ss.141-148, 2009 (SCI-Expanded)
2008
2008Factors affecting the prognosis of breast cancer patients with brain metastases
Saip P., Cicin I., Eralp Y., Kucucuk S., Tuzlali S., Karagol H., et al.
BREAST
, cilt.17, sa.5, ss.451-458, 2008 (SCI-Expanded)
2008
2008Ovarian carcinoma with simultaneous breast and rectum metastases
Derin D., Eralp Y., Guney N., ÖZLÜK M. Y., Topuz E.
Onkologie
, cilt.31, sa.4, ss.200-202, 2008 (SCI-Expanded)
2008
2008Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance
Eralp Y., Sakallioglu B., Kucucuk S., Tuzlali S., Saip P., Igci A., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.26, sa.15, 2008 (SCI-Expanded)
2008
2008MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer
Eralp Y., Derin D., ÖZLÜK M. Y., Yavuz E., Guney N., SAİP P. M., et al.
Annals of Oncology
, cilt.19, sa.4, ss.669-674, 2008 (SCI-Expanded)
2008
2008Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer
GEZER U., Eralp Y., Akisik E. Z., YÖRÜKER E. E., Saip P., Topuz E., et al.
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM V
, cilt.1137, ss.175-179, 2008 (SCI-Expanded)
2008
2008Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer
Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., et al.
CANCER INVESTIGATION
, cilt.26, sa.7, ss.671-679, 2008 (SCI-Expanded)
2008
2008Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy
GEZER U., Eralp Y., YÖRÜKER E. E., Akisik E. Z., Saip P., Topuz E., et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
, cilt.46, sa.3, ss.311-317, 2008 (SCI-Expanded)
2008
2008Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt
Eralp Y., Saip P., Aydin Z., Berkman S., Topuz E.
GYNECOLOGIC ONCOLOGY
, cilt.108, sa.1, ss.248-250, 2008 (SCI-Expanded)
2007
2007Multifocal breast cancer in women <= 35 years old
Litton J. K., Eralp Y., Gonzalez-Angulo A. M., Broglio K., Uyei A., Hortobagyi G. N., et al.
CANCER
, cilt.110, sa.7, ss.1445-1450, 2007 (SCI-Expanded)
2007
2007The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
KARAGÖL H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.
Medical Oncology
, cilt.24, sa.1, ss.39-43, 2007 (SCI-Expanded)
2005
2005Women age <= 35 years with primary breast carcinoma - Disease features at presentation
Gonzalez-Angulo A., Broglio K., Kau S., Eralp Y., Erlichman J., Valero V., et al.
CANCER
, cilt.103, sa.12, ss.2466-2472, 2005 (SCI-Expanded)
2005
2005Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer
Oral E., Aydiner A., Eralp Y., Topuz E.
MEDICAL ONCOLOGY
, cilt.22, sa.4, ss.367-374, 2005 (SCI-Expanded)
2004
2004Thymidine labeling index: Prognostic role in breast cancer
Bilir A., Eralp Y., CABIOĞLU N., Agizhali B., Camlica H., Aydiner A.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.27, sa.4, ss.400-406, 2004 (SCI-Expanded)
2004
2004Women aged 35 years or younger with primary breast carcinoma: Disease features at presentation
Gonzalez-Angulo A. M., Broglio K., Eralp Y., Kau S., Erlichman J., Valero V., et al.
ANNALS OF ONCOLOGY
, cilt.15, ss.58, 2004 (SCI-Expanded)
2004
2004Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
BREAST CANCER RESEARCH
, cilt.6, sa.4, 2004 (SCI-Expanded)
2004
2004Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer
Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., et al.
GYNECOLOGIC ONCOLOGY
, cilt.92, sa.1, ss.147-151, 2004 (SCI-Expanded)
2003
2003Prognostic factors in localized soft-tissue sarcomas.
Kaytan E., Yaman F., Cosar R., Eralp Y., Saip P., Darendeliler E.
American journal of clinical oncology
, cilt.26, ss.411-5, 2003 (SCI-Expanded)
2003
2003Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S., Saip P., Eralp Y., Aydiner A., Topuz E.
American journal of clinical oncology
, cilt.26, sa.4, ss.358-62, 2003 (SCI-Expanded)
2003
2003Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix
Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
, cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded)
2003
2003Prognostic factors in localized aggressive non-Hodgkin's lymphoma
Alici S., Bavbek S. E., Kaytan E., Eralp Y., Onat H.
American Journal of Clinical Oncology: Cancer Clinical Trials
, cilt.26, sa.1, ss.1-5, 2003 (SCI-Expanded)
2003
2003Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.
European journal of gynaecological oncology
, cilt.24, sa.3-4, ss.323-6, 2003 (SCI-Expanded)
2003
2003Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group
Eralp Y., Aydiner A., Kizir A., Kaytan E., Oral E., Topuz E.
CANCER INVESTIGATION
, cilt.21, sa.5, ss.737-743, 2003 (SCI-Expanded)
2002
2002Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: Treatment, outcome, and prognostic factors
Alici S., Bavbek S. E., Kaytan E., Başaran M., Eralp Y., Onat H.
American Journal of Clinical Oncology: Cancer Clinical Trials
, cilt.25, sa.5, ss.502-508, 2002 (SCI-Expanded)
2002
2002Anemia in oncology practice: Relation to diseases and their therapies
TAŞ F., Eralp Y., BAŞARAN M., ŞAKAR B., Alici S., Argon A., et al.
American Journal of Clinical Oncology: Cancer Clinical Trials
, cilt.25, sa.4, ss.371-379, 2002 (SCI-Expanded)
2002
2002Prognostic factors and survival in late adolescent and adult patients with small round cell tumors
Eralp Y., Bavbek S., Başaran M., Kaytan E., Yaman F., Bilgiç B., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.25, sa.4, ss.418-424, 2002 (SCI-Expanded)
2002
2002Clinical characteristics of gestational trophoblastic disease at a single institute
Alici S., Eralp Y., Saip P., Argon A., BAŞARAN M., Topuz E., et al.
Tohoku Journal of Experimental Medicine
, cilt.197, sa.2, ss.95-100, 2002 (SCI-Expanded)
2001
2001Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100) - A phase II study
Basaran M., Bavbek E., Sakar B., Eralp Y., Alici S., TAŞ F., et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.24, sa.6, ss.570-575, 2001 (SCI-Expanded)
2001
2001Thymidine labeling index in epithelial ovarian cancer
Salihoglu Y., Bilir A., Aydiner A., Erkan M., Tuzlali S., Eralp Y.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
, cilt.75, sa.2, ss.171-176, 2001 (SCI-Expanded)
Diğer Dergilerde Yayınlanan Makaleler
2022
2022The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors
Dişel U., Köse F., Bilici A., Özgüroğlu M., Sağlam S., Şeker M., et al.
Journal of Oncological Science
, cilt.8, sa.2, ss.87-93, 2022 (Scopus)
2020
2020Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak
Sezer A., ÇİÇİN İ., Cakmak G. K., Gurdal S. O., Basaran G., Oyan B., et al.
TURKISH JOURNAL OF SURGERY
, cilt.36, sa.2, ss.147-163, 2020 (ESCI)
2018
2018Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes
Ordu C., Pilanci K. N., Alco G., Elbuken F., Koksal U. I., Ilgun S., et al.
EUROPEAN JOURNAL OF BREAST HEALTH
, cilt.14, sa.3, ss.173-179, 2018 (Hakemli Dergi)
2018
2018Impact of Personality Traits, Anxiety, Depression and Hopelessness Levels on Quality of Life in the Patients with Breast Cancer
Izci F., Sarsanov D., Erdogan Z. I., Ilgun A. S., Celebi E., Alco G., et al.
EUROPEAN JOURNAL OF BREAST HEALTH
, cilt.14, sa.2, ss.105-111, 2018 (Hakemli Dergi)
2017
2017Roles of Biopsychosocial Factors in the Development of Breast Cancer
ÖZKAN M., Yildirim N., Disci R., Ilgun A. S., Sarsenov D., Alco G., et al.
EUROPEAN JOURNAL OF BREAST HEALTH
, cilt.13, sa.4, ss.206-212, 2017 (Hakemli Dergi)
2016
2016The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.
Eralp Y.
Translational oncogenomics
, cilt.8, ss.1-7, 2016 (Hakemli Dergi)
2016
2016The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer
Iyigun Z. E., Pilanci K. N., Cabuk F. K., Ilgun S., Ordu C., Duymaz T., et al.
JOURNAL OF BREAST HEALTH
, sa.3, ss.119-122, 2016 (ESCI)
2016
2016The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer
Ordu C., McGuire K., Alco G., Pilanci K. N., Koksal U. I., Elbuken F., et al.
CUREUS
, cilt.8, sa.6, 2016 (Hakemli Dergi)
2016
2016True Local Recurrences after Breast Conserving Surgery have Poor Prognosis in Patients with Early Breast Cancer
Sarsenov D., Ilgun S., Ordu C., Alco G., Bozdogan A., Elbuken F., et al.
CUREUS
, cilt.8, sa.3, 2016 (Hakemli Dergi)
2014
2014The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience
Eralp Y., Kilic L., Alco G., BAŞARAN G., Dogan M., Dincol D., et al.
JOURNAL OF BREAST HEALTH
, cilt.10, sa.4, ss.209-215, 2014 (ESCI)
2002
2002An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; report of a case with literature review.
Alici S., Bavbek S. E., Eralp Y., Argon A., Basaran M., Aydiner A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.7, sa.4, ss.373-6, 2002 (Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
2024Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases
Bayram E., Basaran G., Gokmen E., Mandel N. M., Oyan B., Uskent N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)
2022
2022Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group
Eralp Y., Dogan I., AKSOY S., Cakar B., Basaran G., Ercelep O., et al.
San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2022, (Özet Bildiri)
2022
2022Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Orer H. S., Nomak G., Oksuzoglu B., Senturk R., ERALP Y., Yumuk F., et al.
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 9 - 13 Eylül 2022, (Özet Bildiri)
2020
2020Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.
Disel U., Kose F., Bilici A., ÖZGÜROĞLU M., Saglam S., Seker M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, (Özet Bildiri)
2020
2020Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.
Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)
2019
2019Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey
Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, cilt.80, (Özet Bildiri)
2019
2019Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study
Lu Y., Malwinder S. S., Azim H., Eralp Y., Im S., Yap Y. S., et al.
European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, (Özet Bildiri)
2019
2019Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Kilickap S., Basal F. B., DEMİRKAZIK A., Gursoy P., Demirci U., ERMAN M., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.637, (Özet Bildiri)
2019
2019Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study
El Saghir N., Malwinder S., Azim H., Eralp Y., Im S., Yap Y. S., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.140-141, (Özet Bildiri)
2017
2017The prognostic impact of chemotherapy induced amenorrhea in women treated with early stage breast cancer
Ordu C., Pilanci K. N., Elbuken F., Alco G., Koksal U. I., Ilgun S., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, (Özet Bildiri)
2016
2016Follow-up of chemotherapy induced changes in anti-Mullerian hormone, antral follicle number and ovary volume in premenopausal breast cancer patients
Elbuken F., Ordu C., Sarsenov D., Ilgun S., Pilanci K., Erdogan Z., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)
2016
2016Neoadjuvam kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hangi hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?
Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., et al.
20. Ulusal Cerrahi Kongresi, 2016, Antalya, Türkiye, 13 - 17 Nisan 2016, ss.1, (Tam Metin Bildiri)
2015
2015Metaplastic breast carcinoma versus triple nehative breast cancer survival and response to treatment
AYDINER A., ŞEN F., ÇİFTÇİ R., RÜMEYSA Ç., ERALP Y., SAİP P. M., et al.
MEDİCİNE, 01 Aralık 2015, (Özet Bildiri)
2015
2015Concominant Chemoradiotherapy with Etoposide Cisplatin versus Docetaxel Cisplatin in Locally Advanced Non Small Cell Lung Cancer
ERALP Y., ŞEN F., MAKBULE T., ÖZKAYA K., BERKER Ö., ORAL E. N., et al.
NSCLC, 09 Eylül 2015
2015
2015Does adjuvant chemotherapy induced amenorrhea effect survival in operated premenopausal breast cancer patients
ORDU Ç., ALÇO G., KN P., S, İ., D, S., F, Ç., et al.
European Cancer Congress, 01 Eylül 2015, cilt.322, (Özet Bildiri)
2015
2015Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment
G, A., ORDU Ç., D, S., F, Ç., ERDOĞAN Z., AĞACAYAK F., et al.
EUR J SUR ONCOL, 01 Mayıs 2015, cilt.94, (Özet Bildiri)
2014
2014Aksiller metastazı bulunan hangi hastalarda neoadjuvan kemoterapi sonrasında aksiller diseksiyon yapılmayabilinir?
Karanlık H., Özgür İ., Fayda M., Yavuz E., Mudun A., Saip P. M., et al.
19. Ulusal Cerrahi Kongresi, Antalya, Türkiye, 16 - 20 Nisan 2014, ss.1-1751, (Tam Metin Bildiri)
2006
2006The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., TAŞ F., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.174, (Özet Bildiri)
2004
2004Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model
Eralp Y., Wang X., Wang J., Maughan M., Polo J., Lachman L.
27th Annual Charles A Colman San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 11 Aralık 2004, cilt.88, (Özet Bildiri)
Etkinlik Organizasyonlarındaki Görevler
Ekim 2024
Ekim 2024Breastanbul 2024
Bilimsel Kongre / Sempozyum Organizasyonu
Arıkan A. E., Uras C., Bese F. N., Eralp Y., Aribal M. E., Taşkın F., et al.
İstanbul, Türkiye
Ocak 2024
Ocak 2024
16. Meme Kanserinde Yeni Yaklaşımlar
Bilimsel Kongre / Sempozyum Organizasyonu
Molinas Mandel N., Oyan Uluç B., Arıbal M. E., Beşe N., Çelik L., Esen İçten G., et al.
İstanbul, Türkiye
Mayıs 2023
Mayıs 2023Meme Kanseri Atölye Çalışması
Bilimsel Kongre / Sempozyum Organizasyonu
Arıkan A. E., Eralp Y., Güler S. A., Kıvılcım T., Korkmaz T., Sönmez Ö., et al.
İstanbul, Türkiye
Aralık 2022
Aralık 2022Meme Kanseri Atölye Çalışması
Bilimsel Kongre / Sempozyum Organizasyonu
Arıkan A. E., Korkmaz T., Eralp Y., Sönmez Ö., Yücel S., Güler S. A., et al.
İstanbul, Türkiye
Kongre ve Sempozyum Katılımı Faaliyetleri
17 Ekim 2024 - 20 Ekim 2024
17 Ekim 2024 - 20 Ekim 2024Karadeniz Onkoloji Günleri
Panelist
Trabzon-Türkiye
10 Ekim 2024 - 12 Ekim 2024
10 Ekim 2024 - 12 Ekim 2024Breastanbul
Davetli Konuşmacı
İstanbul-Türkiye
26 Eylül 2024 - 29 Eylül 2024
26 Eylül 2024 - 29 Eylül 2024On Targeted Master Oncology
Oturum Başkanı
İstanbul-Türkiye
23 Eylül 2024 - 23 Eylül 2024
23 Eylül 2024 - 23 Eylül 2024Bahrein Meeting 23 September
Davetli Konuşmacı
Badiyah-Bahreyn
21 Eylül 2024 - 22 Eylül 2024
21 Eylül 2024 - 22 Eylül 20248. Jinekolojik Onkoloji Sempozyumu
Davetli Konuşmacı
İstanbul-Türkiye
07 Eylül 2024 - 08 Eylül 2024
07 Eylül 2024 - 08 Eylül 2024İç Hastalıkları Kongresi
Davetli Konuşmacı
İstanbul-Türkiye
27 Haziran 2024 - 29 Haziran 2024
27 Haziran 2024 - 29 Haziran 2024Uludağ Meme Kanseri Sempozyumu
Davetli Konuşmacı
Bursa-Türkiye
24 Mayıs 2024 - 26 Mayıs 2024
24 Mayıs 2024 - 26 Mayıs 20242. Onkolojide Yenilikler Sempozyumu
Davetli Konuşmacı
Girne-Kıbrıs (Kktc)
10 Mayıs 2024 - 11 Mayıs 2024
10 Mayıs 2024 - 11 Mayıs 2024On Targeted Master Oncology Moleküler Onkoloji
Oturum Başkanı
Ankara-Türkiye
24 Nisan 2024 - 28 Nisan 2024
24 Nisan 2024 - 28 Nisan 202411. Türk Tıbbi Onkoloji Kongresi
Davetli Konuşmacı
Girne-Kıbrıs (Kktc)
27 Mart 2024 - 30 Mart 2024
27 Mart 2024 - 30 Mart 2024Hedef Kanser
Oturum Başkanı
Girne-Kıbrıs (Kktc)
07 Mart 2024 - 09 Mart 2024
07 Mart 2024 - 09 Mart 20247.Karadeniz Meme Kongresi
Davetli Konuşmacı
Samsun-Türkiye
28 Şubat 2024 - 28 Şubat 2024
28 Şubat 2024 - 28 Şubat 2024Temel Bilimlerden Klinik Bİlimlere Araştırma Toplantıları
Davetli Konuşmacı
İstanbul-Türkiye
02 Şubat 2024 - 04 Şubat 2024
02 Şubat 2024 - 04 Şubat 20244. Meme Kanseri Sempozyumu
Davetli Konuşmacı
İstanbul-Türkiye
13 Ocak 2024 - 14 Ocak 2024
13 Ocak 2024 - 14 Ocak 2024